====== Andrew McRae ======

{{ :public_health_agencies:canada:screen_shot_2019-11-26_at_8.19.11_pm.png?150|}}
===== Affiliations =====

==== Alberta Health Services ====

McRae is the emergency department representative for the [[AHS COVID-19 Scientific Advisory Group]] under [[Alberta Health Services]].((//2019-nCoV Scientific Advisory Group.// (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf))

==== Canadian Medical Association ====

McRae is an Editorial Fellow at the [[:Canadian Medical Association]] Journal.((McRae, A. //@Andrew_McRae_EM.// Twitter. Retrieved January 10, 2022, from https://archive.ph/muMc0)) ((//Staff | CMAJ.// Canadian Medical Association Journal. Retrieved January 10, 2022, from https://archive.ph/Y3t9z))

In this capacity, McRae co-authored an editorial titled "{{ :public_health_agencies:canada:e1816.full.pdf |SARS-CoV-2 vaccination should be required to practise medicine in Canada"}}.((McRae, A. D., & Laupacis, A. (2021). //SARS-CoV-2 vaccination should be required to practise medicine in Canada.// Canadian Medical Association Journal, cmaj.211839. https://doi.org/10.1503/cmaj.211839))

==== Ottawa Hospital ====

McRae is a collaborator on a project that addresses ethical and policy challenges posed by cluster randomized trials, in partnership with the Rotman Institute of Philosophy and the [[Ottawa Hospital Research Institute]], funded by the [[Canadian Institutes of Health Research]].((//Andrew McRae.// The Rotman Institute of Philosophy. Retrieved January 10, 2022, from https://www.rotman.uwo.ca/portfolio-items/mcrae-andrew/#tab-5d6239302fa152c2ec9))

The OHRI has received funding for research from [[:pharmaceutical_companies:Pfizer]] for research on drugs for advanced lung cancer,((//Early phase clinical trials shows promising results in advanced lung cancer.// (2011, October 12). Ottawa Hospital Research Institute. https://archive.ph/QMO7q)) kidney transplant patients((Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., Felipe, C. R., Firth, J., Gallon, L., Gelens, M., Glotz, D., Gossmann, J., Guba, M., Morsy, A. A., Salgo, R., & Scheuermann, E. H. (2014). //Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.// BMJ, 349(nov24 1), g6679–g6679. https://doi.org/10.1136/bmj.g6679)) ((Ganton, J. (2015, October 22). //Drugs commonly used in kidney transplant patients not as effective as previously thought.// Ottawa Hospital Research Institute. https://archive.ph/SGtWQ)) and blood clots in cancer patients.((Ganton, J., & Pulkinghorn, I. M. (2018, December 4). //Drug dramatically reduces risk of dangerous blood clots in cancer patients.// Ottawa Hospital Research Institute. https://archive.ph/n6N5h)) ((Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., Trinkaus, M., Tomiak, A., Lee, A. Y. Y., Gross, P. L., Lazo-Langner, A., El-Maraghi, R., Goss, G., Le Gal, G., Stewart, D., & Ramsay, T. (2019). //Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.// The New England Journal of Medicine, 380(8), 711–719. https://doi.org/10.1056/NEJMoa1814468)) 

[[:pharmaceutical_companies:Bristol-Myers Squibb]] also funded the latter study, as did [[:CanVECTOR]], which is funded by [[:pharmaceutical_companies:Alexion]], [[:Aniara Diagnostica]], [[:pharmaceutical_companies:Aspen Pharmacare]], [[:pharmaceutical_companies:Bayer]], [[:bioMérieux]], [[:Boston Scientific]], [[:pharmaceutical_companies:Bristol-Myers Squibb]], [[:Cardinal Health]], [[:pharmaceutical_companies:Daiichi Sankyo]], [[pharmaceutical_companies:LEO Pharma]], [[:pharmaceutical_companies:Pfizer]], and [[:pharmaceutical_companies:Sanofi]].((//Partners//. CanVECTOR. Retrieved January 10, 2022, from https://archive.ph/9TdRm))

Another study looking at blood thinners in pregnancy was also funded by [[:pharmaceutical_companies:Pfizer]], as well as [[:pharmaceutical_companies:Eli Lilly]].((Ganton, J. (2016, October 18). //“Invaluable” study confirms blood thinners don’t prevent recurrent pregnancy complications.// Ottawa Hospital Research Institute. https://archive.ph/yTkEU)) ((Rodger, M. A., Gris, J.-C., de Vries, J. I. P., Martinelli, I., Rey, É., Schleussner, E., Middeldorp, S., Kaaja, R., Langlois, N. J., Ramsay, T., Mallick, R., Bates, S. M., Abheiden, C. N. H., Perna, A., Petroff, D., de Jong, P., van Hoorn, M. E., Bezemer, P. D., & Mayhew, A. D. (2016). //Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.// The Lancet, 388(10060), 2629–2641. https://archive.ph/oithf))

Other pharmaceutical research funders are [[:pharmaceutical_companies:AstraZeneca]],((Ganton, J. (2016, November 2). //Lung cancer breakthrough: 70% of patients with specific mutation respond to new therapy.// Ottawa Hospital Research Institute. https://archive.ph/Hm6x5)) [[:pharmaceutical_companies:Janssen]],((Buchanan, A. (2016, March 30). //When cancer comes back: Drug for mantle-cell lymphoma gives patients more time.// Ottawa Hospital Research Institute. https://archive.ph/qwg6g)) and [[:pharmaceutical_companies:GlaxoSmithKline]].((Buchanan, A. (2019, January 30). //Flu vaccination keeps people with COPD out of the hospital.// Ottawa Hospital Research Institute. https://archive.ph/nu0oI))
==== University of Calgary ====

McRae is a Researcher and Assistant Professor at the [[:University of Calgary]]'s Department of Emergency Medicine, a partnership between [[Alberta Health Services]] and the Cumming School of Medicine.((//Andrew McRae.// (2019, November 26). Cumming School of Medicine. https://archive.ph/oi8C8)) He has a cross-appointment to the Department of Community Health Sciences. In addition to active research interests in emergency department crowding and operations, his primary interest is in health services dimensions of the diagnosis and treatment of cardiovascular emergencies (myocardial infarction, arrhythmias, stroke).

==== Western University ====

McRae was a Postdoctoral Fellow at the Rotman Institute of Philosophy at [[:Western University]] from 2009 – 2011.((//Andrew McRae.// The Rotman Institute of Philosophy. Retrieved January 10, 2022, from https://archive.ph/9RMci))

===== Relationships with Pharmaceutical Companies =====

McRae received an unrestricted research grant from [[:pharmaceutical_companies:Roche]] for 2021-2022.((McRae, A. (2021). //Declaration of competing interests.// Canadian Medical Association Journal. https://archive.ph/AphOI))